The Ochsner Clinical Community Oncology Program proposes to provide NCI supported cancer prevention &control and treatment trials to southern Louisiana utilizing the unique assets of the Ochsner Health System (OHS), the largest integrated health care system in the region. Ochsner CCOP will exceed its trial accrual requirements for the 2011-2016 funding period by completing the restructuring of the CCOP and expanding on our success in the past year through the following Specific Aims:
Specific Aim 1 : Increase accrual to prevention and cancer control as well as treatment trials and optimize the retention of patients on these studies by engaging oncologists across OHS by: I.) Increasing the base of accruing physicians;II.) Utilization of multidisciplinary conferences for patient accrual;and III.) By providing educational incentives.
Specific Aim 2 : Expand the presence of the CCOP in the region through the growing Ochsner community oncology practices and facilitate clinical trial participation of women and minorities through education and outreach programs: I.) Expand the Ochsner CCOP by involving Ochsner community oncology practices as component sites II.) By providing Education and Outreach for providers and the community Specific Aim 3: Consolidate the Ochsner reorganization by a strategic effort aimed at recruitment, training and retention of research staff to support our growing research needs and strengthen our research infrastructure.
Louisiana has cancer incidence and mortality rates above the national average and access to clinical trials is imperative in this region. This demographically diverse region now has an expanded Ochsner presence which provides the Ochsner CCOP with the unique ability to offer state of the art clinical trials to patients close to home.
|Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7|
|Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27|
|Gonsalves, Wilson I; Mahoney, Michelle R; Sargent, Daniel J et al. (2014) Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst 106:|
|Barton, Debra L; Thanarajasingam, Gita; Sloan, Jeff A et al. (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575-83|
|Huang, Jocelin; Nair, Suresh G; Mahoney, Michelle R et al. (2014) Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer 13:100-9|
|Sticca, Robert P; Alberts, Steven R; Mahoney, Michelle R et al. (2013) Current use and surgical efficacy of laparoscopic colectomy in colon cancer. J Am Coll Surg 217:56-62; discussion 62-3|
|Barton, Debra L; Burger, Kelli; Novotny, Paul J et al. (2013) The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 21:1185-92|
|Lavoie Smith, Ellen M; Barton, Debra L; Qin, Rui et al. (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 22:2787-99|
|Alberts, Steven R; Sargent, Daniel J; Nair, Suresh et al. (2012) Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307:1383-93|
|Alberts, Steven R; Reid, Joel M; Morlan, Bruce W et al. (2012) Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial. Am J Clin Oncol 35:418-23|
Showing the most recent 10 out of 71 publications